Full history for every metric is available with a Kvantra account
New Horizon Health Limited (6606.HK)
Key financial summary
Financials in CNY| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY m | - | 19 | 58 | 71 | 213 | 765 | 1,362 |
| Operating profit | CNY m | -160 | -119 | |||||
| Net profit | CNY m | - | -225 | -106 | -789 | -3,085 | -79 | 112 |
| EPS reported | CNY | -0.19 | 0.23 | |||||
| Operating cashflow per share | CNY | -0.99 | -0.99 | |||||
| Capex per share | CNY | 0.13 | 0.13 | |||||
| FCF per share | CNY | -1.12 | -1.12 | |||||
| Free cash flow | CNY m | -466 | -625 | |||||
| Net debt | CNY m | -1,160 | -1,296 | |||||
| Book value equity | CNY m | 2,122 | 2,986 | |||||
| Book value per share | CNY | 5.02 | 6.10 | |||||
| Number of shares | m | 422.93 | 489.3 | |||||
| DPS (TTM paid) | CNY | 0.00 | 0.00 |
Financial summary
Financials in CNY| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 3.05 | 1.82 | |||||
| P/S LTM | x | 8.47 | 3.98 | |||||
| P/FCF LTM | x | -13.90 | -8.68 | |||||
| EV/EBITDA LTM | x | -121.70 | -44.66 | |||||
| EV/Sales LTM | x | 7.31 | 3.03 | |||||
| Earnings Yield LTM | % | -1.22% | -1.57% | |||||
| FCF Yield | % | -7.20% | -11.52% | |||||
| Quality | ||||||||
| ROE | % | -3.73% | -3.73% | |||||
| ROIC | % | -6.69% | -6.69% | |||||
| Operating margin | % | -20.87% | -20.87% | |||||
| Gross margin | % | 84.47% | 84.47% | |||||
| FCF/Sales | % | -60.97% | -60.97% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +259.54% | +245.26% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -1.90 | -1.39 | |||||
| Net Debt/EBITDA | x | 19.28 | 19.28 | |||||
| EBIT/Net interest | x | -21.68 | -21.68 | |||||
| Net debt/market cap | % | -17.90% | -23.90% | |||||
| Net debt/Equity | x | -0.55 | -0.43 | |||||
| Gross debt/equity | x | 0.12 | 0.15 | |||||
Company overview
New Horizon Health Limited functions as an investment holding company, primarily focusing on the research and development of screening products for various cancers, including colorectal and cervical, within the People's Republic of China. The firm also engages in the advancement of medical diagnostic technology. Its operations extend to providing a range of services such as technical support, technology transfers, consulting, medical assistance, and financing. Furthermore, the company manufactures and distributes medical and laboratory equipment, notably specialized fecal occult blood test kits, and is involved in technology import and export activities. Established in 2013, its headquarters are located in Hangzhou, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
New Horizon Health Limited (6606.HK)
New Horizon Health Limited functions as an investment holding company, primarily focusing on the research and development of screening products for various cancers, including colorectal and cervical, within the People's Republic of China. The firm also engages in the advancement of medical diagnostic technology. Its operations extend to providing a range of services such as technical support, technology transfers, consulting, medical assistance, and financing. Furthermore, the company manufactures and distributes medical and laboratory equipment, notably specialized fecal occult blood test kits, and is involved in technology import and export activities. Established in 2013, its headquarters are located in Hangzhou, China.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free